SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
1-Year Return
18.59%
This Quarter Return
+11.78%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.79B
AUM Growth
+$336M
(+14%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
2.33%
Top 10 Holdings %
Top 10 Hldgs %
40.95%
Holding
113
New
14
Increased
21
Reduced
19
Closed
15
Top Buys
| 1 |
Benitec Biopharma
BNTC
|
$65.6M |
| 2 |
Starbucks
SBUX
|
$53.6M |
| 3 |
Capital One
COF
|
$35.3M |
| 4 |
CrowdStrike
CRWD
|
$34.3M |
| 5 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$30.3M |
Top Sells
| 1 |
Arcellx
ACLX
|
$69M |
| 2 |
Insmed
INSM
|
$64.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$50.6M |
| 4 |
Elevance Health
ELV
|
$49.5M |
| 5 |
Sysco
SYY
|
$37.2M |
Sector Composition
| 1 | Healthcare | 59.5% |
| 2 | Technology | 11.2% |
| 3 | Consumer Discretionary | 8.56% |
| 4 | Communication Services | 7.2% |
| 5 | Financials | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Coca-Cola
KO
$294B
| $42.3M | 1.35% |
588,912
+28,299
| +5% | +$2.03M |
|
27
Microsoft
MSFT
$3.78T
| $41.5M | 1.33% |
96,526
-7,507
| -7% | -$3.23M |
|
28
EyePoint Pharmaceuticals
EYPT
$803M
| $41.4M | 1.32% |
5,175,823
| – | – |
|
29
Oracle
ORCL
$625B
| $40.4M | 1.29% |
237,094
-8,020
| -3% | -$1.37M |
|
30
GE Aerospace
GE
$299B
| $37.8M | 1.21% |
200,662
-4,295
| -2% | -$810K |
|
31
Erasca
ERAS
$408M
| $37.6M | 1.2% |
13,768,039
| – | – |
|
|
32
Capital One
COF
$144B
| $35.3M | 1.13% |
+235,600
| New | +$35.3M |
|
|
33
CrowdStrike
CRWD
$104B
| $34.3M | 1.1% |
+122,155
| New | +$34.3M |
|
34
Verizon
VZ
$186B
| $34.1M | 1.09% |
758,674
+148,770
| +24% | +$6.68M |
|
|
CTNM
35
Contineum Therapeutics
CTNM
$302M
| $32.9M | 1.05% |
1,720,000
-333,334
| -16% | -$6.38M |
|
36
McDonald's
MCD
$226B
| $31.6M | 1.01% |
103,638
-6,796
| -6% | -$2.07M |
|
|
BIOA
37
BioAge Labs, Inc. Common Stock
BIOA
$166M
| $30.3M | 0.97% |
+1,455,000
| New | +$30.3M |
|
38
Keurig Dr Pepper
KDP
$39.6B
| $26.4M | 0.84% |
+703,095
| New | +$26.4M |
|
39
Sutro Biopharma
STRO
$84.8M
| $24.9M | 0.8% |
7,187,495
-521,195
| -7% | -$1.8M |
|
40
Las Vegas Sands
LVS
$37.7B
| $24.4M | 0.78% |
+484,110
| New | +$24.4M |
|
41
ProKidney
PROK
$309M
| $23.7M | 0.76% |
12,341,266
+3,000,000
| +32% | +$5.76M |
|
42
Abeona Therapeutics
ABEO
$351M
| $23.3M | 0.75% |
3,685,503
| – | – |
|
43
Johnson & Johnson
JNJ
$428B
| $22.4M | 0.72% |
138,447
+48,350
| +54% | +$7.84M |
|
44
Boston Scientific
BSX
$159B
| $21.1M | 0.67% |
251,689
| – | – |
|
45
Pinterest
PINS
$25.2B
| $19.9M | 0.64% |
615,911
+205,960
| +50% | +$6.67M |
|
46
Zura Bio
ZURA
$134M
| $19.7M | 0.63% |
4,860,939
| – | – |
|
47
PepGen
PEPG
$42M
| $14.2M | 0.45% |
1,660,932
+140,000
| +9% | +$1.2M |
|
48
Monte Rosa Therapeutics
GLUE
$303M
| $14.1M | 0.45% |
2,659,000
| – | – |
|
49
Wynn Resorts
WYNN
$12.7B
| $12.8M | 0.41% |
+133,000
| New | +$12.8M |
|
50
Arcus Biosciences
RCUS
$1.22B
| $10.1M | 0.32% |
663,603
-293,701
| -31% | -$4.49M |
|